Literature DB >> 31111095

International survey of neuromuscular monitoring in two European countries: a questionnaire study among Hungarian and Romanian anaesthesiologists.

Adrienn Pongrácz1, Réka Nemes1, Caius Breazu2, László Asztalos1, Ileana Mitre2, Edömér Tassonyi1, Béla Fülesdi1, Calin Mitre2.   

Abstract

BACKGROUND: Accumulating evidence indicates that objective neuromuscular monitoring and pharmacological reversal of neuromuscular block reduces the occurrence of residual muscle paralysis in the acute postoperative phase. However, objective neuromuscular monitoring is not a routine habit in anaesthesia. In order to change this situation, we wished to find out, as a first step to improvement, the current use of neuromuscular monitors and the custom of anaesthetists for reversal of neuromuscular block before tracheal extubation.
METHODS: A ten-point questionnaire was available via the Surveymonkey website and the link was sent to 2202 Hungarian and Romanian anaesthetists by email.
RESULTS: Three hundred and two (13.7%) of the 2202 registered anaesthetists responded. Less than 10% of them regularly use neuromuscular monitors. They underestimated the occurrence of residual block; only 2.2% gave a correct answer. Neuromuscular monitors are available in 74% of hospitals but are scarcely used. One third of anaesthetists rarely or never use reversal; approximately 20% regularly reverse before extubation. The responders typically believe that clinical signs of residual block are reliable. Instead of monitoring, they use the "timing methods" for tracheal extubation such as time elapsed from last dose, the duration of action of relaxant, the number of top-up doses, the cumulative dose, the return of adequate respiratory tidal volume and the ability to sustain a 5 s head lift.
CONCLUSIONS: We concluded that neuromuscular monitoring in these two European countries is suboptimal as is the reversal strategy. Given the fact that monitors are available in the hospitals, the mentality should be changed towards evidence based practice.

Entities:  

Keywords:  neuromuscular blocking agents; neuromuscular monitoring; residual neuromuscular block; survey

Year:  2019        PMID: 31111095      PMCID: PMC6502274          DOI: 10.2478/rjaic-2019-0007

Source DB:  PubMed          Journal:  Rom J Anaesth Intensive Care        ISSN: 2392-7518


  32 in total

1.  A study of the deaths associated with anesthesia and surgery: based on a study of 599, 548 anesthesias in ten institutions 1948-1952, inclusive.

Authors:  H K BEECHER; D P TODD
Journal:  Ann Surg       Date:  1954-07       Impact factor: 12.969

2.  Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9.

Authors:  Florent Capron; Francois Alla; Claire Hottier; Claude Meistelman; Thomas Fuchs-Buder
Journal:  Anesthesiology       Date:  2004-05       Impact factor: 7.892

3.  Postoperative residual paralysis in outpatients versus inpatients.

Authors:  Guy Cammu; Jan De Witte; Jan De Veylder; Geert Byttebier; Dirk Vandeput; Luc Foubert; Geert Vandenbroucke; Thierry Deloof
Journal:  Anesth Analg       Date:  2006-02       Impact factor: 5.108

4.  A new concept in the measurement of neuromuscular transmission and block.

Authors:  E Tassonyi
Journal:  Anaesthesist       Date:  1975-08       Impact factor: 1.041

5.  Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.

Authors:  Glenn S Murphy; Joseph W Szokol; Jesse H Marymont; Steven B Greenberg; Michael J Avram; Jeffery S Vender
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

6.  Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit.

Authors:  Glenn S Murphy; Joseph W Szokol; Jesse H Marymont; Steven B Greenberg; Michael J Avram; Jeffery S Vender; Margarita Nisman
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

7.  Impact of anesthesia management characteristics on severe morbidity and mortality.

Authors:  M Sesmu Arbous; Anneke E E Meursing; Jack W van Kleef; Jaap J de Lange; Huub H A J M Spoormans; Paul Touw; Frans M Werner; Diederick E Grobbee
Journal:  Anesthesiology       Date:  2005-02       Impact factor: 7.892

Review 8.  Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis.

Authors:  M Naguib; A F Kopman; J E Ensor
Journal:  Br J Anaesth       Date:  2007-03       Impact factor: 9.166

9.  The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium.

Authors:  E Sundman; H Witt; R Olsson; O Ekberg; R Kuylenstierna; L I Eriksson
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

10.  Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade.

Authors:  Matthias Eikermann; Harald Groeben; Johannes Hüsing; Jürgen Peters
Journal:  Anesthesiology       Date:  2003-06       Impact factor: 7.892

View more
  3 in total

1.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

2.  Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study From the Multicenter Perioperative Outcomes Group.

Authors:  Timur Z Dubovoy; Leif Saager; Nirav J Shah; Douglas A Colquhoun; Michael R Mathis; Steven Kapeles; Graciela Mentz; Sachin Kheterpal; Michelle T Vaughn
Journal:  Anesth Analg       Date:  2020-11       Impact factor: 6.627

3.  Neuromuscular Blocking Agents and Monitoring in China: A Cross-Sectional Survey of Current Management.

Authors:  HaoTian Wu; ZengMao Lin; RuiHao Zhou; SuiSui Huang; LingJun Chen; Yang Su; LuoNa Cheng; Huan Zhang
Journal:  Front Med (Lausanne)       Date:  2022-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.